Is Halozyme Stock (HALO) Halal? A Complete Analysis

The Short Answer

Halozyme stock (HALO) is generally considered halal by most Islamic scholars and Sharia screening criteria, with convertible-note leverage as the primary consideration. Halozyme licenses its drug-delivery enzyme technology to pharmaceutical partners in exchange for royalties.

Development and licensing of pharmaceutical drug-delivery technology is a permissible healthcare activity at the activity level. The main consideration is the financial screen: Halozyme has issued convertible senior notes, so the debt-to-market-cap ratio should be verified against the 33% threshold at the time of investment.

Sharia Screening Methodology

Islamic scholars use several criteria to screen stocks:

• Business activity screen: Is the company's primary business halal?
• Debt ratio: Total debt / market cap must be under 33%
• Interest income: Interest income / total revenue must be under 5%
• Haram revenue: Revenue from haram sources must be under 5%
• Receivables ratio: Total receivables / total assets must be under 49–70% (varies by board)

Halozyme's Business Activity

Halozyme generates revenue from:

• ENHANZE royalties: Its recombinant human hyaluronidase enzyme enables subcutaneous delivery of partners' biologic drugs
• Milestone payments: Earned as partner programs advance and launch
• Proprietary products: A smaller specialty-products portfolio

This is a permissible healthcare and pharmaceutical-technology business at the activity level.

Concerns to Be Aware Of

1. Convertible-Note Leverage — The Primary Screen

Halozyme has issued convertible senior notes to fund growth and share buybacks. The debt-to-market-cap ratio should be verified against the 33% Sharia threshold at the time of investment, though the company is strongly profitable and highly cash-generative. This is the primary Sharia-screening consideration.

2. Interest-Bearing Instruments

Convertible notes are interest-bearing instruments. Investors who object to any conventional-debt issuance should weigh this even where the debt ratio passes the 33% screen.

3. Partner Concentration

Royalty revenue is concentrated in a relatively small set of partner drugs, and a partner-patent or competitive event could affect results. This is a business consideration rather than a Sharia screen concern.

Financial Ratios (2025)

Based on Halozyme's most recent financial statements:

• Total Debt / Market Cap: Convertible-note leverage — verify against the 33% threshold at the time of investment ⚠️
• Interest Income / Revenue: Under 5% — verify ✅
• Haram Revenue: Negligible (drug-delivery licensing) ✅
• Business Activity: Permissible healthcare / pharma technology ✅

Verdict from Major Screening Agencies

Halozyme stock is generally screened as compliant (halal) with purification, subject to leverage verification by:

• Zoya App — Generally compliant, verify financials ✅
• MSCI Islamic criteria — Generally included subject to ratios ✅
• Most major Sharia advisory boards — Compliant with purification, subject to debt-ratio verification ✅

Bottom Line

Halozyme (HALO) is generally halal with purification for Muslim investors, subject to verifying the debt ratio at the time of investment. The core business — licensing drug-delivery technology — is a permissible healthcare activity. Because Halozyme carries convertible-note leverage, the most important step is confirming the debt-to-market-cap ratio sits below the 33% threshold, then purifying a small portion of any interest income.

For Muslim investors seeking healthcare and biopharma exposure, HALO sits alongside other halal-screened names like Eli Lilly (LLY) and Exelixis (EXEL).